US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
Alicia Keys, Brian d’Arcy James, Daniel Radcliffe and more react to earning Tony Award nominations
Singer Alicia Keys says she was unable to speak after her semi-autobiographical show “Hell’s Kitchen2024-05-01Language Service Added to China's Emergency Response
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-01'Drifters' Bring New Vitality to Ancient Xinjiang City
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-01Free Extracurricular Classes Nurture Talents of Tibetan Children
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-01Walmart shutting down its 51 health care clinics, virtual care service
Walmart is closing its health centers and virtual care service after struggling to find success with2024-05-01Shanghai International Film Festival ready for action this June
Shanghai International Film Festival (SIFF) announced that the annual event will take place from Jun2024-05-01
atest comment